In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...
The convergence of AI, quantum computing, and biosciences is propelling the global healthcare industry into a new era - now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback